JOHN HARRISON HEILIGENSTEIN, M.D.
Psychiatric at Braedonwood, Indianapolis, IN
License number
Indiana 01043276A
Category
Medical Practice
Type
Developmental - Behavioral Pediatrics
License number
Indiana 01043276A
Category
Neurology
Type
Neurodevelopmental Disabilities
License number
Indiana 01043276A
Category
Psychiatric
Type
Child & Adolescent Psychiatry
Address
Address
4470 Braedonwood, Indianapolis, IN 46228
Phone
(317) 225-1449
Personal information
See more information about JOHN HARRISON HEILIGENSTEIN at radaris.comName
Address
Phone
4470 Braedonwood, Indianapolis, IN 46228
Indianapolis, IN
747 Kessler Boulevard West Dr, Indianapolis, IN 46228
4470 Braedonwood, Indianapolis, IN 46228
Professional information
Dr. John H Heiligenstein, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Child & Adolescent Psychiatry, Pediatric Psychiatry
Address:
747 Kessler Boulevard West Dr, Indianapolis 46228
(317) 254-8820 (Phone)
(317) 254-8820 (Phone)
Certifications:
Child Psychiatry, 1984, Pediatrics, 1977, Psychiatry, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Loyola University of Chicago / Stritch School of Medicine
Graduated: 1971
Childrens Memorial Hospital
Ky Med Ctr
Ny Hosp-Cornell
U Virginia
Loyola University of Chicago / Stritch School of Medicine
Graduated: 1971
Childrens Memorial Hospital
Ky Med Ctr
Ny Hosp-Cornell
U Virginia
Treatment Of Attention-Deficit/Hyperactivity Disorder
US Patent:
5658590, Aug 19, 1997
Filed:
Jan 11, 1995
Appl. No.:
8/371341
Inventors:
John H. Heiligenstein - Indianapolis IN
Gary D. Tollefson - Indianapolis IN
Gary D. Tollefson - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 920, A61K 31135
US Classification:
424464
Abstract:
Tomoxetine, a norepinephrine uptake inhibitor, is used to treat attention-deficit/hyperactivity disorder.
Treatment Of Attention-Deficit/Hyperactivity Disorder
US Patent:
6046193, Apr 4, 2000
Filed:
Sep 17, 1998
Appl. No.:
9/156284
Inventors:
John Harrison Heiligenstein - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31535
US Classification:
5142392
Abstract:
Reboxetine is used to treat attention-deficit/hyperactivity disorder.
Treatment Of Conduct Disorder
US Patent:
6184222, Feb 6, 2001
Filed:
Sep 17, 1998
Appl. No.:
9/156285
Inventors:
John Harrison Heiligenstein - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31535
US Classification:
5142392
Abstract:
Norepinephrine reuptake inhibitors are used to treat conduct disorder.
Treatment Of Attention-Deficit/Hyperactivity Disorder
US Patent:
5696168, Dec 9, 1997
Filed:
Jul 16, 1996
Appl. No.:
8/682040
Inventors:
John Harrison Heiligenstein - Indianapolis IN
Bennett Coleman Laguzza - Indianapolis IN
Steven Marc Paul - Carmel IN
Gary Dennis Tollefson - Indianapolis IN
Bennett Coleman Laguzza - Indianapolis IN
Steven Marc Paul - Carmel IN
Gary Dennis Tollefson - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31135
US Classification:
514649
Abstract:
A group of propanamines, norepinephrine uptake inhibitors, are used to treat attention-deficit/hyperactivity disorder.
Treatment Of Oppositional Defiant Disorder
US Patent:
6028070, Feb 22, 2000
Filed:
Sep 17, 1998
Appl. No.:
9/156289
Inventors:
John Harrison Heiligenstein - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31535, A61K 3138, A61K 31165, A61K 31135
US Classification:
5142388
Abstract:
Norepinephrine reuptake inhibitors are used to treat oppositional defiant disorder.